Podcast

Pharmacy Focus: Psychedelic Pharmacy - Episode 2

Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.

In the second episode of the Psychedelic Pharmacy series, Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research. In the interview, Nyquvest said he believes psychedelics will lead to a major shift in the mental health treatment paradigm in the next 3 to 5 years.

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Trisha Winroth, PharmD, and Ashly McPhillips, PharmD
Naloxone concept represented by wooden letter tiles.
Related Content
Hidradenitis Suppurative, FDA, Dermatology, Bimzelx | Image Credit: © Gorodenkoff | stock.adobe.com
Published: November 20th 2024 | Updated: November 20th 2024

FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa

Ashley Gallagher, Associate Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Diversity, Pharmacy, Student Exchange, Pharmacy Student | Image Credit: © Studio Romantic | stock.adobe.com
November 13th 2024

Student Exchange Program Crafts Cultural Competency for Pharmacists

Rena Reid, PharmD
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Diabetes, Cagrilintinide, Semagliutide | Image Credit: millaf - stock.adobe.com
November 11th 2024

An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 Trials

Vidhi Patel, PharmD Candidate
Spinal health visualization Individual suffering spinal muscular dystrophy glowing depiction of progressive muscle weakness affecting the spine
November 8th 2024

FDA Grants Orphan Drug Designation to Ifetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Luke Halpern, Assistant Editor